The effect of elevated α1-acid glycoprotein on the pharmacokinetics of TAK-272 (SCO-272), an orally active renin inhibitor, in rats.

The pharmacokinetics of TAK-272 (SCO-272), an orally active renin inhibitor, was investigated in rats with subcutaneously injected turpentine oil, which was an inflammation animal model. Following intravenous administration of TAK-272 to the turpentine-treated rats, the systemic clearance and volume of distribution decreased with the elevated plasma α1-acid glycoprotein (AGP) levels. The elevated plasma AGP levels were negatively correlated with the plasma unbound fraction of TAK-272 in the rats. Although the AUCs of total TAK-272 in the turpentine-treated rats were higher than those in the control rats after intravenous and oral administration, those of unbound TAK-272, which seem to directly contribute to the pharmacological effect and safety, were nearly equal between the turpentine-treated and control rats in the respective dose routes. TAK-272 has been shown to primarily bind to AGP in the human plasma. These results strongly suggested that the pharmacokinetic of TAK-272 in humans would also be affected by the variation in the plasma AGP levels and should be discussed with not only the total concentrations but also the unbound concentrations in the clinical trial for patients with elevated plasma AGP levels.

Short term inhalation exposure to turpentine: toxicokinetics and acute effects in men.

OBJECTIVES: This study describes the toxicokinetics, pulmonary function, and subjective ratings of discomfort in volunteers experimentally exposed to turpentine vapour (a mixture of monoterpenes). The results were compared with similar exposure to single monoterpenes to look in the toxicokinetics and acute effects for signs of interactions between the monoterpenes. METHODS: Eight male volunteers were exposed to 450 mg/m3 turpentine by inhalation (2 h, 50 W) in an exposure chamber. RESULTS: The mean relative uptakes of alpha-pinene, beta-pinene, and 3-carene were 62%, 66%, and 68% respectively, of the amount supplied. Between 2% and 5% of the net uptake was excreted unchanged in the expired air after the end of exposure. The mean blood clearance 21 hours after exposure (CL21h) of alpha-pinene, beta-pinene and 3-carene, were 0.8, 0.5, and 0.4 l.kg-1.h-1, respectively. The mean half lives (t1/2) of the last phase of alpha-pinene, beta-pinene, and 3-carene averaged 32, 25, and 42 hours, respectively. The t1/2s agreed with previously calculated half lives from single exposures. The total blood clearance CL21h of 3-carene found in this turpentine study was lower, and CL4h of 3-carene was significantly lower than the values obtained from similar exposure to pure 3-carene. The subjects attending both exposure to turpentine and to pure alpha-pinene at 450 mg/m3 had lower CL4h during the exposure to turpentine, when they experienced more discomfort of the throat or the airways (F = 5.7, P = 0.048) than during exposure to control concentrations. After experimental exposure to turpentine an increase in airway resistance was found that differed significantly from results of exposure to 3-carene at 10 mg/m3 (P = 0.021) or 450 mg/m3 (P = 0.047). CONCLUSIONS: Toxicokinetics and acute effects show small, if any, interactions between alpha-pinene, beta-pinene, and 3-carene. The subjects experienced discomfort in the throat and airways during exposure to turpentine and airway resistance was increased after the end of exposure.